RNF10

E3 ubiquitin-protein ligase RNF10 · Q8N5U6 · RNF10 on Sugi Atlas →

0 patent compounds predicted against RNF10, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RNF10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) PHASE1COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Implication of Genetic Variations in Long Intergenic Non-coding RNA 00511 (LINC00511) in Colorectal Cancer nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Role of Polymorphisms in the IL-1 Gene Cluster nanCOMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RNF10 binder may also engage these)

ProteinNameSimilarity
Q08E13 1.000 Q08E13 →
Q5XI59 1.000 Q5XI59 →
Q3UIW5 1.000 Q3UIW5 →
Q32NQ8 0.999 Q32NQ8 →
P61406 0.995 P61406 →
Q9NQW6 0.994 Q9NQW6 →
Q6DD45 0.993 Q6DD45 →
Q5HZN1 0.993 Q5HZN1 →
Q5R789 0.993 Q5R789 →
Q9CYA6 0.992 Q9CYA6 →
A0JMK9 0.992 A0JMK9 →
Q3UB74 0.992 Q3UB74 →
Q92613 0.992 Q92613 →
LARP1 La-related protein 1 0.992 landscape →
Q1LYM3 0.992 Q1LYM3 →
Q76LL6 0.992 Q76LL6 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.992 landscape →
Q9BQK8 0.992 Q9BQK8 →
Q5PQK8 0.992 Q5PQK8 →
Q1LUT1 0.992 Q1LUT1 →
Q640U0 0.992 Q640U0 →
Q28E45 0.992 Q28E45 →
Q9PTP2 0.992 Q9PTP2 →
Q9CSP9 0.992 Q9CSP9 →
Q6ZPS6 0.991 Q6ZPS6 →
Q5RAK6 0.991 Q5RAK6 →
A6QP06 0.991 A6QP06 →
Q9I9K7 0.991 Q9I9K7 →
Q7Z3E5 0.991 Q7Z3E5 →
O08623 0.991 O08623 →